Drugs in R & D

, Volume 5, Issue 6, pp 351–354 | Cite as

Palifermin

AMJ 9701, KGF — Amgen, Recombinant Human Keratinocyte Growth Factor, rHu-KGF
Adis R&D Profile

Keywords

Lipase Placebo Recipient Metastatic Colorectal Cancer Oral Mucositis Serum Amylase 

References

  1. 1.
    Durrant S, Pico JL, Schmitz N, et al. A phase I study of recombinant human keratinocyte growth factor in lymphoma patients receiving high-dose chemotherapy with autologous peripheral blood progenitor cell transplantation. Blood 94 (Suppl. 1): 708, Part 1, 15 Nov 1999Google Scholar
  2. 2.
    Meropol NJ, Gutheil J, Pelley R, et al. Keratinocyte growth factor as a mucositis protectant: a randomized phase I trial. 36th Annual Meeting of the American Society of Clinical Oncology 19: 603, 20 May 2000Google Scholar
  3. 3.
    Amgen Inc. Phase 3 Data Show Palifermin Improves Patient Reported Outcomes in Cancer Patients and Helps Reduce Hospitalizations and Healthcare Resources. Media Release: 9 Dec 2003. Available from URL: http://www.amgen.com
  4. 4.
    Amgen Inc. Phase 3 Data Suggest Palifermin Significantly Reduces the Duration and Incidence of Oral Mucositis in Cancer Patients. Media Release: 1 Jun 2003. Available from URL: http://www.amgen.com Google Scholar
  5. 5.
    Panoskaltsis-Mortari A, Lacey DL, Vallera DA. Keratinocyte growth factor administered before conditioning ameliorates graft-versus-host disease after allogeneic bone marrow transplantation in mice. Blood 92: 3960–3967, 15 Nov 1998PubMedGoogle Scholar
  6. 6.
    Amgen. Amgen’s KGF shows preliminary efficacy in preventing chemotherapy-induced severe oral mucositis. Media Release [4 pages]: 14 May 2001. Available from URL: http://www.amgen.com
  7. 7.
    Amgen. Amgen Announces Positive Results of Phase 3 Study for rHu-KGF. Media Release: 23 Jan 2003. Available from URL: http://www.amgen.com
  8. 8.
    Stiff P, Bensinger W, Emmanouilides C, et al. Treatment of mucositis with palifermin improves patient function and results in a clinically meaningful reduction in mouth and throat soreness: phase 3 results. Blood 102: 194, No. 11, Part 1, 16 Nov 2003Google Scholar
  9. 9.
    Emmanouilides C, Spielberger R, Stiff P, et al. Palifermin treatment of mucositis in transplant patients reduces health resource use: phase 3 results. Blood 102: 251–252, No. 11, Part 1, 16 Nov 2003Google Scholar

Copyright information

© Adis Data Information BV 2004

Personalised recommendations